Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jul 11;21(10):1714–1720. doi: 10.1016/j.bbmt.2015.07.002

Table 2.

Post-transplant cellular therapy approaches aimed at decreasing disease relapse after haploidentical transplantation

Approach Advantages and limitations
Unmodified DLI(37–40)

  • Increase graft-versus-malignancy effect

  • Non-selective
Unmodified DLI with a “safety switch”(41–46)

  • Increase graft-versus-malignancy effect

  • Control of GVHD, if develops

  • Non-selective
γδ donor T cell infusion(49–54, 57, 58, 86)

  • Infusion of selected gamma-delta T cells

  • No GVHD potential

  • Unclear efficacy
T cells with chimeric antigen receptors (CARs)(60–62)

  • T cells engineered to recognize specific antigens (e.g. CD19) provides graft-versus-malignancy effect for B-cell lymphoid malignancies (ALL, NHL)

  • Efficacy demonstrated in small series

  • No GVHD potential
Infusion of ex vivo expanded NK cells(80–85)

  • Potential graft-versus-malignancy for myeloid malignancies

  • No GVHD

  • Efficacy unclear

DLI - donor lymphocyte infusion; GVHD – graft-versus-host disease; ALL – acute lymphoblastic leukemia; NHL – non-Hodgkin’s lymphoma; NK – natural killer cells; CAR – chimeric antigen receptor